natgillin/translations-raw huggingface dataset:
De har svært nedsat nyrefunktion
you have severely reduced kidney function
De har svært nedsat nyrefunktion to eller flere af følgende punkter gælder for Dem:
you have severely reduced kidney function
De har tanker om at skade Dem selv eller har selvmordstanker.
You have thoughts of harming or killing yourself.
De har urinsyregigt.
you have gout.
De har ustabil angina pectoris (nyopståede eller tiltagende brystsmerter)
you have unstable angina pectoris (new or increasing chest pain)
De har usædvanlig langsom hjerterytme eller andre hjerteproblemer.
You have an exceptionally slow heart rate or other heart problems.
de har utilsigtet vægttab, anæmi, gastrointestinal blødning, dysphagi, vedvarende opkastninger eller opkastning med blod, da det kan sløre symptomerne og derved forsinke en diagnose af en alvorlig lidelse.
They have unintentional weight loss, anaemia, gastrointestinal bleeding, dysphagia, persistent vomiting or vomiting with blood, since it may alleviate symptoms and delay diagnosis of a severe condition.
de har været i vedvarende symptomatisk behandling for fordøjelsesbesvær eller halsbrand, som varer i 4 uger eller længere
They have been on continuous symptomatic treatment of indigestion or heartburn for 4 or more weeks.
De her anførte bivirkninger er grupperet efter, hvor ofte de kan forekomme:
The side effects are listed below, grouped by how likely they are to happen.
De hidtidige erfaringer viste lovende resultater for Tagrissos evne til at mindske svulstens størrelse.
The evidence available so far showed promising results in terms of Tagrisso’s ability to reduce tumour size.
De histologiske fund hos mennesker har vist hepatisk nekrose og galdestase.
The histological findings in man have shown hepatic necrosis and biliary stasis.
De hjertefrekvens- korrigerede QT-intervaller hos duloxetin-behandlede patienter adskilte sig ikke fra dem, der blev observeret i placebogruppen.
The heart rate-corrected QT interval in duloxetine-treated patients did not differ from that seen in placebo-treated patients.
De hjertefrekvens- korrigerede QT-intervaller hos duloxetinbehandlede patienter adskilte sig ikke fra dem, der blev observeret i placebogruppen.
The heart rate-corrected QT interval in duloxetine-treated patients did not differ from that seen in placebo-treated patients.
De hjertefrekvenskorrigerede QT-intervaller hos duloxetin-behandlede patienter adskilte sig ikke fra dem, der blev observeret i placebogruppen.
The heart rate-corrected QT interval in duloxetine-treated patients did not differ from that seen in placebo-treated patients.
De hjælper immunforsvaret med målrettet at ramme bestemte celler ved at ‘klæbe’ til dem.
They help the immune system to target certain cells, such as cancer cells, by ‘sticking’ to them.
De hormonale antikonceptiva bør indeholde
norgestimate as the progestagen or
De hunde, der blev behandlet med Trifexis, blev sammenlignet med hunde, der var behandlet med milbemycinoxim alene.
Trifexis-treated dogs were compared to dogs treated with milbemycin oxime alone.
De hunde, der blev behandlet med Vectra 3D, fik i løbet af 4 uger i gennemsnit mindsket antallet af flåter med 94 %, sammenlignet med 97 % i kontrolgruppen.
The dogs treated with Vectra 3D had an average tick reduction of 94% compared with 97% in the control group over 4 weeks.
De hvide til grålighvide filmovertrukne tabletter på 5 mg er ovale-aflange tabletter præget med ”5” på den ene side og ”MEM” på den anden side.
The 5 mg film-coated tablets are white to off-white, oval-oblong film-coated tablets with imprint ‘5’ on one side and imprint ‘MEM’ on the other side.
De hyppigeste NCI-CTCAE (version 3) grad 3-4 bivirkninger (≥ 10 %) var neutropeni, febril neutropeni og leukopeni.
The most common NCI-CTCAE v.3 Grade 3-4 ADRs (≥10%) were neutropenia, febrile neutropenia and leucopenia.
De hyppigeste NCI-CTCAE version 3 grad 3-4 bivirkninger (≥ 10%) var neutropeni, febril neutropeni, anæmi, leukopeni og diarré.
The most common NCI-CTCAE v.3 Grade 3-4 ADRs (≥10%) were neutropenia, febrile neutropenia, anaemia, leucopenia and diarrhoea.
De hyppigheder, der tildeles bivirkningerne, er baseret på rå incidensrater observeret med Brimica Genuair 340 mikrogram/12 mikrogram i den poolede analyse af randomiserede, placebokontrollerede kliniske fase III-studier af mindst seks måneders varighed.
The frequencies assigned to the adverse reactions are based on crude incidence rates observed with Brimica Genuair 340 micrograms /12 micrograms in the pooled analysis of randomised, placebo-controlled Phase III clinical studies of at least six months duration.
De hyppigheder, der tildeles bivirkningerne, er baseret på rå incidensrater observeret med Duaklir Genuair 340 mikrogram/12 mikrogram i den poolede analyse af randomiserede, placebokontrollerede kliniske fase III-studier af mindst seks måneders varighed.
The frequencies assigned to the adverse reactions are based on crude incidence rates observed with Duaklir Genuair 340 micrograms /12 micrograms in the pooled analysis of randomised, placebo-controlled Phase III clinical studies of at least six months duration.
De hyppigst (> 25 % af forsøgspersonerne) påviste post-baseline RAVer hos disse forsøgspersoner var aminosyre-substitutionerne V36M (61 %) og R155K (68 %) hos forsøgspersoner inficeret med genotype 1a-vira og T54A (42 %), T54S (37 %), A156S (26 %) og V170A (32 %) hos forsøgspersoner inficeret med genotype 1b-vira.
The most frequently (> 25% of subjects) detected post-baseline RAVs in these subjects were amino acid substitutions V36M (61%) and R155K (68%) in subjects infected with genotype 1a viruses and T54A (42%), T54S (37%), A156S (26%) and V170A (32%) in subjects infected with genotype 1b viruses.
De hyppigst (> 5 % af behandlede voksne patienter) rapporterede bivirkninger med kombination af fosamprenavir/ritonavir er gastrointestinale reaktioner (kvalme, diarré, mavesmerter og opkastning) og hovedpine.
The most frequently (> 5% of adult subjects treated) reported adverse reactions with fosamprenavir/ritonavir combination were gastrointestinal reactions (nausea, diarrhoea, abdominal pain and vomiting) and headache.
De hyppigst beskrevne eller observerede alvorlige bivirkninger var:
The most frequent reported or observed serious adverse drug reactions were:
De hyppigst detekterede NS5A-RAV’er omfattede Q30E eller Q30R i kombination med L31M.
The most frequently detected NS5A RAVs included Q30E or Q30R in combination with L31M.
De hyppigst forekommende (≥ 5 % af patienterne) bivirkninger var alle i systemorganklassen mave- tarm-kanalen.
The most frequently occurring (≥5% of patients) adverse reactions were all in the gastrointestinal disorders system organ class.
De hyppigst forekommende (≥ 5 % af patienterne) bivirkninger var alle i systemorganklassen mave-tarm- kanalen.
The most frequently occurring (≥ 5% of patients) adverse reactions were all in the gastrointestinal disorders system organ class.
De hyppigst forekommende (≥ 5 % af patienterne) bivirkninger var alle i systemorganklassen mave-tarm- kanalen.
The most frequently occurring (≥5% of patients) adverse reactions were all in the gastrointestinal disorders system organ class.
De hyppigst forekommende bivirkninger (≥ 5 % af patienterne) var alle i systemorganklassen mave- tarm-kanalen.
The most frequently occurring (≥5% of patients) adverse reactions were all in the gastrointestinal disorders system organ class.
De hyppigst forekommende bivirkninger er opkastning, kvalme og konstipation.
The most common adverse reactions are vomiting, nausea and constipation.
De hyppigst forekommende bivirkninger ved behandling af ansigt og hovedbund:
The most frequently occurring side effects when treating the face and scalp:
De hyppigst forekommende bivirkninger ved behandling af kroppen og ekstremiteter:
The most frequently occurring side effects when treating the trunk and extremities:
De hyppigst forekommende bivirkninger ved INCRELEX er: Lavt blodsukker (hypoglykæmi), opkastning, reaktioner ved injektionsstedet, hovedpine og mellemørebetændelse.
The most frequently occurring side effects with INCRELEX are: low blood sugar (hypoglycemia), vomiting, injection site reactions, headache and middle ear infections.
De hyppigst forekommende bivirkninger ved LEMTRADA (hos ≥ 20 % af patienterne) er udslæt, hovedpine, feber og luftvejsinfektioner.
The most common adverse reactions with LEMTRADA (in ≥20% of patients) are rash, headache, pyrexia, and respiratory tract infections.
De hyppigst forekommende bivirkninger ved Privigen (som ses hos flere end 1 ud af 10 patienter) er hovedpine, kvalme, opkastning, diarré, hudlidelser (herunder udslæt), smerte (bl.a. i ryggen, halsen, lemmerne, leddene og ansigtet), feber, influenzalignende sygdomstegn, træthed, afkræftelse og smerte på injektionsstedet.
The most common side effects with Privigen (seen in more than 1 patient in 10) are headache, nausea, vomiting, diarrhoea, skin disorders (including rashes), pain (including in the back, neck, limbs, joints and face), fever, a flu-like illness, tiredness, weakness and pain at the injection site.
De hyppigst forekommende OI'er i kliniske undersøgelser var candidiasis, cytomegalovirus, herpes simplex, Pneumocystis carinii pneumoni og mycobakterium avium kompleks.
The most frequently observed OI’s in clinical studies were candidiasis, cytomegalovirus, herpes simplex, Pneumocystis carinii pneumonia, and mycobacterium avium complex.
De hyppigst forekommende okulære bivirkninger efter behandling med Lucentis er: øjensmerter, okulær hyperæmi, øget intraokulært tryk, vitrit, corpus vitreum-løsning, nethindeblødning, synsforstyrrelser, mouches valantes, konjunktival blødning, øjenirritation, fornemmelse af fremmedlegeme i øjnene, øget tåreflåd, blepharitis, tørt øje og øjenkløe.
The most frequently reported ocular adverse reactions following injection of Lucentis are: eye pain, ocular hyperaemia, increased intraocular pressure, vitritis, vitreous detachment, retinal haemorrhage, visual disturbance, vitreous floaters, conjunctival haemorrhage, eye irritation, foreign body sensation in eyes, increased lacrimation, blepharitis, dry eye and eye pruritus.
De hyppigst forekommende rapporterede bivirkninger (ADRs) ( 15 %) ved dabrafenib var hyperkeratose, hovedpine, pyreksi, artralgi, træthed, kvalme, papillom, alopeci, udslæt og opkastning.
The most frequently occurring adverse drug reactions (ADRs) (15%) reported with dabrafenib were hyperkeratosis, headache, pyrexia, arthralgia, fatigue, nausea, papilloma, alopecia, rash and vomiting.
De hyppigst iagttagne bivirkninger omfatter perifer sensorisk eller motorisk neuropati, træthed, kvalme, diarré, neutropeni, opkastning, feber og infektioner.
The most frequent side effects include peripheral sensory or motor neuropathy, tiredness, nausea (feeling sick), diarrhoea, neutropenia, vomiting, fever, infections and cough.
De hyppigst indberettede andre samtidige sygdomme (med en cut-off på 30% eller derover) i MedDRA-systemet var: Vaskulære sygdomme (73%), hjertesygdomme (46%), sygdomme i mave- tarm-kanalen (38%), stofskifte- og ernæringssygdomme (40%), sygdomme i nyrer og urinveje (38%), sygdomme i knogler, led, muskler og bindevæv (33%).
The most frequently reported coexisting medical conditions (using a cut off of 30% or higher), in the MedDRA body systems are: Vascular disorders (73%), Cardiac disorders (46%), Gastrointestinal disorders (38%), Metabolism and nutrition disorders (40%), Renal and urinary disorders (38%), Musculoskeletal and connective tissue disorders (33%).
De hyppigst indberettede bivirkninger (>10 %) med brivaracetambehandling var: døsighed (14,3 %) og svimmelhed (11,0 %).
The most frequently reported adverse reactions (>10%) with brivaracetam treatment were: somnolence (14.3 %) and dizziness (11.0 %).
De hyppigst indberettede bivirkninger (som forekom hos ≥ 5 % af patienterne, der fik tocilizumab- monoterapi eller kombinationsbehandling med DMARDs) var øvre luftvejsinfektioner, nasopharyngitis, hovedpine, hypertension og forhøjet ALAT.
The most commonly reported ADRs (occurring in ≥ 5% of patients treated with tocilizumab monotherapy or in combination with DMARDs) were upper respiratory tract infections, nasopharyngitis, headache, hypertension and increased ALT.
De hyppigst indberettede bivirkninger (som forekom hos ≥ 5 % af patienterne, der fik tocilizumab- monoterapi eller kombinationsbehandling med DMARDs) var øvre luftvejsinfektioner, nasopharyngitis, hovedpine, hypertension og forhøjet ALAT.
The most commonly reported Adverse Drug Reactions (ADRs) (occurring in ≥ 5% of patients treated with tocilizumab monotherapy or in combination with DMARDs) were upper respiratory tract infections, nasopharyngitis, headache, hypertension and increased ALT.
De hyppigst indberettede bivirkninger ( 5%) blandt abataceptbehandlede patienter var hovedpine, kvalme og infektioner i de øvre luftveje.
The most frequently reported adverse reactions (≥ 5%) among abatacept-treated patients were headache, nausea, and upper respiratory tract infections.
De hyppigst indberettede bivirkninger efter administration af Vaxelis var irritabilitet, gråd, somnolens, reaktioner på injektionsstedet (smerter, erythem, hævelse), pyreksi (≥ 38 oC), nedsat appetit og opkastning.
The most frequently reported adverse reactions after Vaxelis administration were irritability, crying, somnolence, injection site reactions (pain, erythema, swelling), pyrexia (≥38oC), decreased appetite, and vomiting.
De hyppigst indberettede bivirkninger efter mindst 12 måneders opfølgning hos patienter med nyligt diagnosticeret CML i kronisk fase, som er blevet behandlet med SPRYCEL, var væskeretention (inklusive pleuraeffusion) (19%), diarré (17%), hovedpine (12%), udslæt (11%), muskuloskeletale smerter (11%), kvalme (8%), træthed (8%), myalgi (6%), opkastning (5%) og muskelinflammation (4%).
Based on a minimum of 12 months follow-up the most frequently reported adverse reactions in SPRYCEL-treated patients with newly diagnosed chronic phase CML were fluid retention (including pleural effusion) (19%), diarrhoea (17%), headache (12%), rash (11%), musculoskeletal pain (11%), nausea (8%), fatigue (8%), myalgia (6%), vomiting (5%), and muscle inflammation (4%).
De hyppigst indberettede bivirkninger er artralgi og influenzalignende symptomer.
. The most frequently reported adverse reactions were arthralgia and influenza-like symptoms.
De hyppigst indberettede bivirkninger er artralgi og influenzalignende symptomer.
The most frequently reported adverse reactions were arthralgia and influenza-like symptoms.
De hyppigst indberettede bivirkninger er gastrointestinale gener (såsom diarré og kvalme), symptomer fra nervesystemet (såsom svimmelhed, hovedpine og somnolens) og træthed.
The most commonly reported adverse reactions are gastrointestinal disorders (such as diarrhoea, nausea), nervous system disorders (such as dizziness, headache, somnolence) and fatigue.
De hyppigst indberettede bivirkninger er gener fra mave-tarmsystemet (såsom diarré og kvalme), symptomer fra nervesystemet (såsom svimmelhed, hovedpine og søvnighed) og træthed.
The most commonly reported side effects are gastrointestinal disorders (such as diarrhoea, nausea), nervous system disorders (such as dizziness, headache, somnolence) and fatigue.
De hyppigst indberettede bivirkninger er kvalme og opkastning baseret på de tilgængelige data fra patienter, der har fået cinacalcet i placebokontrollerede studier og enkeltarms-studier.
Based on available data from patients receiving cinacalcet in placebo controlled studies and single-arm studies the most commonly reported adverse reactions were nausea and vomiting.
De hyppigst indberettede bivirkninger er nausea og opkastning baseret på de tilgængelige data fra patienter, der har fået cinacalcet i placebokontrollerede studier og enkeltarms-studier.
Based on available data from patients receiving cinacalcet in placebo controlled studies and single-arm studies the most commonly reported adverse reactions were nausea and vomiting.
De hyppigst indberettede bivirkninger er øvre gastrointestinale bivirkninger, herunder abdominalsmerter, dyspepsi, øsofageal ulcus, dysfagi, abdominal udspiling og syreregurgitation (> 1 %).
The most commonly reported adverse reactions are upper gastrointestinal adverse reactions including abdominal pain, dyspepsia, oesophageal ulcer, dysphagia, abdominal distension and acid regurgitation (> 1 %).
De hyppigst indberettede bivirkninger er:
The most frequently reported side effects are:
De hyppigst indberettede bivirkninger hos patienter med resistens eller intolerans over for tidligere behandling med imatinib, som blev behandlet med SPRYCEL, var væskeretention (inklusive pleuraeffusion), diarré, hovedpine, kvalme, udslæt, dyspnø, blødning, træthed, muskuloskeletale smerter, infektion, opkastning, hoste, abdominal smerter og pyreksi.
The most frequently reported adverse reactions in SPRYCEL-treated patients with resistance or intolerance to prior imatinib therapy were fluid retention (including pleural effusion), diarrhoea, headache, nausea, skin rash, dyspnoea, haemorrhage, fatigue, musculoskeletal pain, infection, vomiting, cough, abdominal pain and pyrexia.
De hyppigst indberettede bivirkninger i pivotale forsøg med primær hyperkolesterolæmi og blandet dyslipidæmi i de anbefalede doser var nasopharyngitis (4,8 %), infektion i øvre luftveje (3,2 %), rygsmerter (3,1 %), artralgi (2,2 %), influenza (2,3 %) og kvalme (2,1 %).
The most commonly reported adverse drug reactions during primary hypercholesterolaemia and mixed dyslipidaemia pivotal trials, at the recommended doses, were nasopharyngitis (4.8%), upper respiratory tract infection (3.2%), back pain (3.1%), arthralgia (2.2%), influenza (2.3%), and nausea (2.1%).
De hyppigst indberettede bivirkninger i placebokontrollerede forsøg, som er indrapporteret hos ≥ 5 % af de patienter, der blev behandlet med Onglyza 5 mg og hyppigere end hos de patienter, der blev behandlet med placebo, er øvre luftvejsinfektion (7,7 %), urinvejsinfektion (6,8 %) og hovedpine (6,5 %).
The most commonly reported adverse reactions in placebo-controlled trials reported in ≥5% of patients treated with Onglyza 5 mg and more commonly than in patients treated with placebo are upper respiratory tract infection (7.7%), urinary tract infection (6.8%) and headache (6.5%).
De hyppigst indberettede bivirkninger med NexoBrid er lokale smerter og pyreksi (feber) eller hyper- termi (forhøjet legemstemperatur).
The most commonly reported side effects with NexoBrid are local pain, and pyrexia (fever) or hyperthermia (high body temperature).
De hyppigst indberettede bivirkninger var diarré (42 %) og udslæt (24 %).
The most commonly reported adverse drug reactions (ADRs) were diarrhoea (42%) and rash (24%).
De hyppigst indberettede bivirkninger var infektioner i de øvre luftveje (som oftest nasopharyngitis, rhinitis).
The most frequently reported adverse drug reactions (ADRs) were upper respiratory tract infections (most frequently nasopharyngitis, rhinitis).
De hyppigst indberettede bivirkninger ved Caprelsa er diarré, udslæt, kvalme (utilpashed), højt blodtryk (hypertension) og hovedpine.
The most commonly reported side effects with Caprelsa are diarrhoea, rash, nausea (feeling sick), hypertension (high blood pressure) and head ache.
De hyppigst indberettede bivirkninger ved elvitegravir var diarré (7,1 %) og kvalme (4,0 %) (se tabel 3).
The most frequently reported adverse reactions to elvitegravir were diarrhoea (7.1%) and nausea (4.0%) (see Table 3).
De hyppigst indberettede bivirkninger ved Pergoveris (set hos flere end 1 ud af 10 patienter) er hovedpine, æggestokcyster og reaktioner på injektionsstedet (f.eks. smerte, kløe, rødme, blå mærker, hævelse eller irritation på injektionsstedet).
The most common side effects reported with Pergoveris (seen in more than 1 patient in 10) are headache, ovarian cysts and injection site reactions (e.g. pain, itching, redness, bruising, swelling or irritation at the site of injection).
De hyppigst indberettede bivirkninger, der forekom hyppigere ved vaccine end ved placebo, var pyreksi (20,9 %), diarré (17,9 %) og opkastning (10,1 %).
The most commonly reported adverse reactions that occurred more frequently with vaccine than with placebo were pyrexia (20.9 %), diarrhoea (17.6 %) and vomiting (10.1 %).
De hyppigst indberettede bivirkninger, som blev anset for at have en mulig eller sandsynlig forbindelse til Stribild i kliniske studier med behandlingsnaive patienter, var kvalme (16 %) og diarré (12 %) (samlede data fra fase 3-kliniske studier GS-US-236-0102 og GS-US-236-0103 til og med 144 uger).
The most frequently reported adverse reactions considered possibly or probably related to Stribild in clinical studies of treatment-naïve patients were nausea (16%) and diarrhoea (12%) (pooled data from Phase 3 clinical studies GS-US-236-0102 and GS-US-236-0103, through 144 weeks).
De hyppigst indberettede overfølsomhedssymptomer omfatter kvalme, udslæt, dyspnø, rygsmerter, brystgener (herunder trykken for brystet), urticaria, artralgi og hovedpine.
The most frequently reported symptoms of hypersensitivity include nausea, rash dyspnoea, back pain, chest discomfort (including chest tightness), urticaria, arthralgia, and headache.
De hyppigst indberettede reaktioner på injektionssteder var erythem, smerter og blå mærker på injektionsstederne.
The most frequent injection site reactions were injection site erythema, injection site pain and injection site bruising.
De hyppigst indberettede symptomer på overfølsomhed omfatter kvalme, udslæt, dyspnø, rygsmerter, brystgener (herunder trykken for brystet), urticaria, artralgi og hovedpine.
The most frequently reported symptoms of hypersensitivity include nausea, rash, dyspnoea, back pain, chest discomfort (including chest tightness), urticaria, arthralgia, and headache..
De hyppigst indberettede uønskede reaktioner i de forskellige konditioneringer, der omfatter thiotepa, er: infektioner, cytopeni, aGvHD og cGvHD, gastrointestinale sygdomme, hæmorragisk cystitis og slimhindeinflammation.
The most frequently adverse reactions reported in the different conditioning treatments including thiotepa are: infections, cytopenia, acute GvHD and chronic GvHD, gastrointestinal disorders, haemorrhagic cystitis, mucosal inflammation.
De hyppigst indrapporterede bivirkninger er hæmatologiske forstyrrelser (anæmi, neutropeni) og metaboliske forstyrrelser (hyperlactatæmi, hyperlipasæmi).
The main adverse events reported are haematological disorders (anaemia, neutropenia), metabolic disorders (hyperlactatemia, hyperlipasemia).
De hyppigst indrapporterede bivirkninger er hæmatologiske forstyrrelser (anæmi, neutropeni) og metaboliske forstyrrelser (hyperlipasemi).
The main adverse reactions reported are haematological disorders (anaemia, neutropenia), metabolic disorders ( hyperlipasemia).
De hyppigst indrapporterede symptomer (≥ 5%) associeret med en infusionsrelateret reaktion var kvalme, træthed, kulderystelser, hypotension, pyreksi, opkastning, dyspnø, ansigtsrødme, hypertension, hovedpine, takykardi, svimmelhed og diarré.
Most frequently reported (≥5%) symptoms associated with an IRR were nausea, fatigue, chills, hypotension, pyrexia, vomiting, dyspnea, flushing, hypertension, headache, tachycardia, dizziness and diarrhoea.
De hyppigst observerede bivirkninger (hos mindst 5 % af de patienter, der blev behandlet med Eylea) var konjunktivalblødning (25 %), nedsat visus (11 %), øjensmerter (10 %), katarakt (8 %), forhøjet intraokulært tryk (8 %), løsning af glaslegemet (7 %) og glaslegemeflydere (7 %).
The most frequently observed adverse reactions (in at least 5% of patients treated with Eylea) were conjunctival haemorrhage (25%), visual acuity reduced (11%), eye pain (10%), cataract (8%), intraocular pressure increased (8%), vitreous detachment (7%) and vitreous floaters (7%).
De hyppigst observerede bivirkninger (≥ 10 %) hos patienter, der fik Xofigo, var diaré, kvalme, opkastning og trombocytopeni.
The most frequently observed adverse reactions (≥ 10%) in patients receiving Xofigo were diarrhoea, nausea, vomiting and thrombocytopenia.